Oral Alpan

Oral Alpan

Auto-generated profile, based on publicly available information

Oral Alpan

Amerimmune Fairfax VA USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2021 in Allergy
Verified
Journal Article
Open access
PDF file
ASAlexandra F Figueira Santos
Alexandra F Figueira Santos
OAOral Alpan
Oral Alpan
HHHans‐Jürgen Hoffmann
Hans‐Jürgen Hoffmann
The basophil activation test (BAT) is a functional assay that measures the degree of degranulation following stimulation with allergen or controls by flow cytometry. It correlates directly with histamine release. From the dose‐response curve resulting from BAT in allergic patients, basophil reactivity (%CD63+ basophils) and basophil sensitivity (EC50 or similar) are the main outcomes of the test. BAT takes into account all characteristics of IgE and allergen and thus can be more specific than sensitization tests in the diagnosis of allergic disease. BAT reduces the need for in vivo procedures, such as intradermal tests and allergen challenges, which can cause allergic reactions of unpredictable severity. As it closely reflects the patients' phenotype in most cases, it may be used to support the diagnosis of food, venom and drug allergies and chronic urticaria, to monitor the natural resolution of food allergies and to predict and monitor clinical the response to immunomodulatory treatments, such as allergen‐specific immunotherapy and biologicals. Clinical application of BAT requires analytical validation, clinical validation, standardization of procedures and quality assurance to ensure reproducibility and reliability of results. Currently, efforts are ongoing to establish a platform that could be used by laboratories in Europe and in the USA for quality assurance and certification.

15 May 2021 in Allergy
Verified
Journal Article
Open access
PDF file
MPMatthew Plassmeyer
Matthew Plassmeyer
OAOral Alpan
Oral Alpan
MCMichael J. Corley
Michael J. Corley
TPThomas A Premeaux
Thomas A Premeaux
KLKimberleigh Lillard
Kimberleigh Lillard
RGRaavi Gupta
Raavi Gupta
Background: COVID‐19 can present with lymphopenia and extraordinary complex multiorgan pathologies that can trigger long‐term sequela.Aims: Given that inflammasome products, like caspase‐1, play a role in the pathophysiology of a number of co‐morbid conditions, we investigated caspases across the spectrum of COVID‐19 disease.Materials & Methods: We assessed transcriptional states of multiple caspases and using flow cytometry, the expression of active caspase‐1 in blood cells from COVID‐19 patients in acute and convalescent stages of disease. Non‐COVID‐19 subject presenting with various comorbid conditions served as controls.Results: Single‐cell RNA‐seq data of immune cells from COVID‐19 patients showed a distinct caspase expression pattern in T cells, neutrophils, dendritic cells, and eosinophils compared with controls. Caspase‐1 was upregulated in CD4+ T‐cells from hospitalized COVID‐19 patients compared with unexposed controls. Post‐COVID‐19 patients with lingering symptoms (long‐haulers) also showed upregulated caspase‐1activity in CD4+ T‐cells that ex vivo was attenuated with a select pan‐caspase inhibitor. We observed elevated caspase‐3/7levels in red blood cells from COVID‐19 patients compared with controls that was reduced following caspase inhibition.Discussion: Our preliminary results suggest an exuberant caspase response in COVID‐19 that may facilitate immune‐related pathological processes leading to severe outcomes. Further clinical correlations of caspase expression in different stages of COVID‐19 will be needed.Conclusion: Pan‐caspase inhibition could emerge as a therapeutic strategy to ameliorate or prevent severe COVID‐19.

1 November 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
AKAlexander Kroemer
Alexander Kroemer
KKKhalid Khan
Khalid Khan
MPMatthew Plassmeyer
Matthew Plassmeyer
OAOral Alpan
Oral Alpan
MHM.A. Haseeb
M.A. Haseeb
TFThomas M. Fishbein
Thomas M. Fishbein

8 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MDMikail Dogan
Mikail Dogan
LKLina Kozhaya
Lina Kozhaya
LPLindsey Placek
Lindsey Placek
CGCourtney L. Gunter
Courtney L. Gunter
MYMesut Yigit
Mesut Yigit
DUDerya Unutmaz
Derya Unutmaz
Development of antibody protection during SARS-CoV-2 (CoV-2) infection is a pressing question for public health and for vaccine development. We developed highly sensitive CoV-2-specific antibody and neutralization assays. CoV-2 Spike protein or Nucleocapsid protein specific IgG antibodies at titers more than 1:100,000 were detectable in all PCR+ subjects (n=87) and were absent in the negative controls. Other isotype antibodies (IgA, IgG1-4) were also detected. CoV-2 neutralization was determined in COVID-19 and convalescent plasma up to 10,000-fold dilution, using Spike protein pseudotyped lentiviruses, which was also blocked by neutralizing antibodies (NAbs). Hospitalized patients had up to 3000-fold higher antibody and neutralization titers compared to outpatients or convalescent plasma donors. Further, subjects who donated plasma further out from the diagnosis of COVID-19 appeared to have lower titers. Interestingly, some COVID-19 patients also contained NAbs against SARS Spike protein pseudovirus. Together these results demonstrate the high specificity and sensitivity of our assays, which may impact understanding the quality or duration of the antibody response during COVID-19 and in determining the effectiveness of potential vaccines.

4 February 2021 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
PDF file
TKTheodore Kim
Theodore Kim
JYJing Yu
Jing Yu
HLHenry Li
Henry Li
MSMark Scarupa
Mark Scarupa
RWRichard L. Wasserman
Richard L. Wasserman
SSSøren Ulrik Sønder
Søren Ulrik Sønder
Background: The short stability window of several hours from blood collection to measuring basophil activation has limited the use of flow cytometry‐based basophil activation assays in clinical settings. We examine if it is possible to extend this window to 1 day allowing for shipment of samples between laboratories. Several options exist for reporting the results including reporting all the measured values directly, calculating ratios and reporting a single value covering all measured results. Each of these options have different stability and value to the physician.Methods: Whole blood samples from peanut allergic patients were stimulated with four different peanut concentrations at Day 0, Day 1, and Day 2. Samples were stored under temperature‐controlled conditions. Flow cytometry was used to analyze the samples. The basophil activation and degranulation were measured as percentage of positive CD63 basophils and CD203c MFI fold change. Shipped samples were transported under ambient conditions.Results: The results show that CD63 is a stable marker at Day 1. The CD203c ratio decreases significantly at Day 1. Calculating the CD63/IgE ratio proves to be more stable than CD63 alone. The most stable readouts are the semi‐quantitative results and the trajectory of the dose response curve. Finally, we confirmed that the stability can be extended to samples shipped overnight to the laboratory.Conclusions: It is possible to extend the stability of the basophil activation assay to 1 day for samples stored at 18–25°C as well as samples shipped under ambient conditions as long as the temperature is within the 2–37°C range.

9 September 2020 in Allergy
Verified
Journal Article
Open access
PDF file
OAOral Alpan
Oral Alpan
JLJanice A. Layhadi
Janice A. Layhadi
SSSøren Ulrik Sønder
Søren Ulrik Sønder
HLHenry Li
Henry Li
MSMohamed H. Shamji
Mohamed H. Shamji
For decades, the approach to clinical care has involved the assessment of a fairly small set of patients' signs and symptoms, sampled over a short period of time with limited attention given to individual variations in aetiology and pathophysiology. Subsequently, a therapy is assigned predominantly with a "one shoe fits all" approach. Precision medicine approaches are now starting to change ways to test, treat and develop new therapies for allergic and immunological disorders. (Figure 1).